Investigation launched into GeneDx after Q1 revenue misses expectations by $12M

Holzer & Holzer, LLC is investigating GeneDx Holdings Corp. for potential violations of federal securities laws following the company's Q1 2026 report. GeneDx revealed its revenue was $12 million below expectations due to lower reimbursement rates and weaker performance in noncore business lines, causing its stock price to drop. Investors who suffered losses are encouraged to contact the law firm to discuss legal options. This investigation highlights concerns about the company's financial disclosures and future outlook.